Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Dexamethasone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 known ✓ | P04150 | 9/20 | 0.82 |
| ▸ | CYP3A4 | P08684 | 7/20 | 0.82 |
| ▸ | HIF1A | Q16665 | 7/20 | 0.82 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.82 |
| ▸ | PGR | P06401 | 4/20 | 0.82 |
| ▸ | NFKB1 | P19838 | 3/20 | 0.82 |
| ▸ | TSHR | P16473 | 2/20 | 0.82 |
| ▸ | AR | P10275 | 2/20 | 0.82 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.82 |
| ▸ | MEN1 | O00255 | 2/20 | 0.82 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.82 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.82 |
| ▸ | APEX1 | P27695 | 1/20 | 0.82 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.82 |
| ▸ | IKBKB | O14920 | 1/20 | 0.82 |
| ▸ | CHUK | O15111 | 1/20 | 0.82 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.82 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.82 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.82 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.82 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dexamethasone SCHEMBL2940262 | 1.00 | NR3C1 (0.82) | NR3C1CYP3A4HIF1AHSD17B10PGR | |
| Dexamethasone SCHEMBL2933729 | 1.00 | NR3C1 (0.82) | NR3C1CYP3A4HIF1AHSD17B10PGR | |
| Betamethasone SCHEMBL29047992 | 1.00 | NR3C1 (0.82) | NR3C1CYP3A4HIF1AHSD17B10PGR | |
| Dexamethasone SCHEMBL2933295 | 1.00 | NR3C1 (0.82) | NR3C1CYP3A4HIF1AHSD17B10PGR | |
| Dexamethasone SCHEMBL25246105 | 1.00 | NR3C1 (0.82) | NR3C1CYP3A4HIF1AHSD17B10PGR | |
| Dexamethasone SCHEMBL93889 | 1.00 | NR3C1 (0.82) | NR3C1CYP3A4HIF1AHSD17B10PGR | |
| Dexamethasone SCHEMBL25248831 | 1.00 | NR3C1 (0.82) | NR3C1CYP3A4HIF1AHSD17B10PGR | |
| Dexamethasone SCHEMBL25292805 | 1.00 | NR3C1 (0.82) | NR3C1CYP3A4HIF1AHSD17B10PGR | |
| Dexamethasone SCHEMBL5151472 | 1.00 | NR3C1 (0.82) | NR3C1CYP3A4HIF1AHSD17B10PGR | |
| Dexamethasone SCHEMBL25247721 | 0.99 | NR3C1 (0.83) | NR3C1CYP3A4HIF1AHSD17B10PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240156960-A1 | SYSTEMS AND METHODS FOR EXPRESSING BIOMOLECULES IN A SUBJECT | DNARx (US) | 2024-05-16 | — | — | US | disclosed |
| EP-4216935-A1 | SYSTEMS AND METHODS FOR EXPRESSING BIOMOLECULES IN A SUBJECT | Dnarx (US) | 2023-08-02 | — | — | EP | disclosed |
| US-20230212610-A1 | NUCLEIC ACID EXPRESSION USING SUBCUTANEOUS ADMINISTRATION | DNARx (US) | 2023-07-06 | — | — | US | disclosed |
| WO-2023122535-A2 | NUCLEIC ACID EXPRESSION USING SUBCUTANEOUS ADMINISTRATION | DNARx (US) | 2023-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240156960-A1 | SYSTEMS AND METHODS FOR EXPRESSING BIOMOLECULES IN A SUBJECT | ACE2, ACE, IGF2BP2 | NR3C1 312/4885CYP3A4 4808/4885HIF1A 1570/4885 |
| US-20230212610-A1 | NUCLEIC ACID EXPRESSION USING SUBCUTANEOUS ADMINISTRATION | FABP4, APMAP, IGF2BP2 | NR3C1 1388/4885CYP3A4 4879/4885HIF1A 3700/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.